Kremer, Daniel M. http://orcid.org/0000-0001-6224-0550
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA237421, R01CA248160, R01CA244931)
Article History
Received: 21 January 2021
Accepted: 14 February 2022
First Online: 28 April 2022
Competing interests
: C.A.L. has received consulting fees from Astellas Pharmaceuticals and Odyssey Therapeutics and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox-control pathways in cancer and targeting the GOT1 pathway as a therapeutic approach.